Sai Life Sciences Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7cat9xgrtqt7m12tarp49r5s.pdf

Key Takeaways


Business Model & Competitive Position

Krishna Kanumuri: "I don't think anybody has this footprint at this point. So I think our business model is uniquely different enough and we're deep enough across the value chain, which is really creating this upside potential for us."

CDMO Performance & Pipeline

Krishna Kanumuri: "It's basically timing of commercial launch, successful or failure of commercial launch. So, essentially, we're an industry which is basically cyclical and doesn't have a straight-line growth projection."

CRO & Discovery Growth

Krishna Kanumuri: "But the environment is still very tough and very hard to read right now because they're just reacting to the Tariff news and it's all relatively new."

New Modalities Investment

Krishna Kanumuri: "In this way, we're not following the molecule, we're following our customer, if I would put it that way."

Margins & Financial Management


Demand Environment & Supply Chain Shift

Krishna Kanumuri: "Right now, it's mostly supply chain shift. I think that's what you have to attribute it to more than anything else. It's not like the sector is doing any more different than usual, but I think the supply chain shift is a major factor."

Guidance & Commitments

CommitmentSpecificsTimeline
Long-term EBITDA margin28% to 30%Over the next couple of years, within a 3-5 year period
Long-term revenue growth CAGR15% to 20%Over a 3-5 year period
FY26 capexClose to ₹700 crores, with ~₹550 crores currently planned; funded from internal accruals, debt, and remaining IPO moneyFY26
Capacity increaseClose to ~30% addition from new manufacturing capacityOne part in November, another half in May
ROCEMid-to-high-teen ROCEOngoing commitment, currently being met
Interest costsLower interest costs expectedFrom FY26
New modalities capex₹50 crores to ₹70 croresOngoing build-out

Key Metrics

MetricQ4 FY25
Revenue from operations (FY25)₹1,695 cr, +16% YoY from ₹1,465 cr in FY24
EBITDA (FY25)₹425 cr, +42% YoY from ₹300 cr in FY24
EBITDA margin (FY25)25%, up from 20% in FY24; long-term target 28–30%
Profit after tax (FY25)₹170 cr, +105% YoY from ₹83 cr in FY24
ROCE (FY25)12%, up from 10% in FY24
Revenue mix (FY25)CDMO 63%, CRO 37%
CRO revenue growth (FY25)~26% YoY
Large pharma share in CRO37–38%, up from ~30% last year
Large pharma share in CDMO~70% large pharma, 30% biotech
Capacity utilization (FY25)67%
Capex (FY25)₹408 cr
Planned capex (FY26)₹700+ cr, with ~₹550 cr based on current visibility; 60–65% manufacturing, 35% R&D
Maintenance capex~₹70 cr
New modalities capex (FY26)₹50–70 cr for peptides, ADCs, oligos
Working capital days (FY25)117 days
Debt repayment (FY25)₹720 cr completed from IPO proceeds
FTE strength growth (FY25)~27% YoY; FY26 expected growth 12–15%
Overseas centers revenue (FY25)$14–15 mn, EBITDA profitable
Discovery business split60% discovery chemistry, 40% biology services (DMPK and biology)
Q4 one-time provision~₹34 cr against delayed customer billing, 2% impact on FY25 revenue
Q1 FY25 EBITDA margin9%, versus 25–27% in subsequent quarters due to CDMO seasonality
Capacity increase (FY26)~30% from new manufacturing lines coming online